Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Private equity firm jumps into vascular health with new investment
Vascular Technology, first founded 40 years ago, is planning on using the new funds to grow and expand its portfolio.
At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.
What can federal health agencies do to revive the fading trust of the public?
Confidence in public health entities is spiraling downward in the U.S., and once-revered Washington institutions like the CDC and NIH are among the casualties in serious condition. How to break the negative momentum?
Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data
The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.
AAP, other physician societies double down on Kennedy-crossing vaccination stance
5 high-profile physician leaders: ‘Misinformation, politicization of commonsense public health efforts and sudden changes to federal vaccine guidance are creating mass confusion and diminishing trust in public health.’

FDA approves new fast-acting insulin for type 1 and type 2 diabetes

The approval was based on data from two phase III randomized, treat-to-target studies.

Hospitals are already treating COVID-19 patients with common steroid

Hospitals in the U.S. are already using dexamethasone, a commonly known steroid that’s readily available and inexpensive, to treat COVID-19 patients without waiting for confirmation of preliminary results from a British study that found the drug can greatly improve survival.

Infective endocarditis after TAVR: 4 key findings from a new study of 7,000 patients

Infective endocarditis is a relatively rare complication of TAVR, but the infection can be fatal when it does strike.

Specialists share experience prescribing a historically expensive cardiovascular medication

Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

Significant portion of COVID-19 may be asymptomatic

Between 40% and 45% of COVID-19 infections could be in people who display no symptoms of the illness, according to an analysis by Scripps Research published in Annals of Internal Medicine.

The top 10 hospitals for pediatric cardiology care

Such attributes as patient outcomes, efficiency and available resources were used to develop the list, which includes a tie at No. 10.

Treating type 2 diabetes with ertugliflozin does not increase risk of major cardiovascular events

The VERTIS CV Study tracked the performance of ertugliflozin and a placebo in more than 8,000 adult T2D patients.

Azithromycin associated with greater risk of cardiovascular death, but not sudden cardiac death

Outpatient prescriptions for azithromycin are associated with an increased risk of cardiovascular mortality, according to new research published in JAMA Network Open.

Clinical

Private equity firm jumps into vascular health with new investment

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving

What can federal health agencies do to revive the fading trust of the public?

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data

AAP, other physician societies double down on Kennedy-crossing vaccination stance